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Abstract: Patients with atrial fibrillation discontinuing anticoagulant therapy are left unprotected against ischaemic stroke. Fur-
ther, switching between oral anticoagulants may be associated with a transiently increased risk of bleeding or thromboembolism.
However, there is a paucity of real-life data on pattern of switching and discontinuation of oral anticoagulants. To address this,
we conducted a nationwide drug utilization study including all registered Danish atrial fibrillation patients initiating a non-VKA
oral anticoagulant (NOAC) between August 2011 and February 2016. We assessed changes in anticoagulant treatment, including
switching between oral anticoagulants and discontinuation of NOACs, and explored patient characteristics predicting these chan-
ges.We identified 50,632 patients with atrial fibrillation initiating NOAC therapy within the study period. The majority initiated
dabigatran (49.9%) and one-third had previously used VKA. Within 1 year, 10.1% switched to VKA, 4.8% switched to another
NOAC and 14.4% discontinued treatment. The frequencies of switching to VKA and discontinuation were highest among NOAC
users of young age (<55 years) and with low CHA2DS2-VASc score (=0). However, the majority of patients (87.3%) stopping
NOAC treatment had a CHA2DS2-VASc score ≥1.We conclude that switching from VKA to NOAC, and to a lesser extent from
NOAC to VKA, is common, as is early treatment discontinuation. The majority of treatment changes are observed in patients at
increased risk of stroke. More research is warranted on the risks of bleeding and thromboembolism associated with switching
and discontinuation of NOACs as well as the underlying reasons why these treatment changes occur.
Non-vitamin K antagonist oral anticoagulants (NOACs) were
introduced as stroke prophylaxis in patients with atrial fibrilla-
tion (AF) in 2011 [1]. Since then, the uptake of NOAC in
western countries, including Denmark, has been massive [2,3].
Further, many patients are switched from a vitamin K antago-
nist (VKA) to a NOAC [4,5]. While switching from VKA to
NOAC is generally assumed to be safe [6], switching from
NOAC to VKA was associated with an increased risk of both
bleeding and thromboembolism in post hoc analyses of ran-
domized, clinical trials [7,8]. So far, only few studies have
provided real-life data on the extent of anticoagulant switching
from NOAC to VKA, and the rates have differed substantially
[4,9–11].
The benefits of NOACs on certain safety outcomes, for
example lower risk of intracerebral haemorrhage [12], are the
main reason why several scientific societies recommend
NOAC over VKA [1,13]. However, the expected clinical
benefit of NOAC may be offset by subsequent switches to
VKA or discontinuation. The aim of this study was to estab-
lish whether switching and discontinuation of oral anticoagu-
lants occurs at an extent that should lead to such concerns.
We therefore conducted a nationwide, register-based drug
utilization study and explored switching and discontinuation
during NOAC therapy including frequency, patient characteris-
tics and predictors among AF patients initiating NOAC ther-
apy in Denmark during 2011–2016.
Materials and Methods
Using nationwide registries, we identified patients with AF initiating
NOAC therapy and assessed their baseline characteristics, including
prior VKA use. We tabulated treatment changes using descriptive
statistics and analysed potential predictors for discontinuation or
switching between oral anticoagulants by use of multivariable mod-
elling.
Data sources. We obtained data from three registries: the Danish
National Prescription Registry [14] (‘Prescription Registry’), the
Danish National Patient Registry [15] (‘Patient Registry’) and the
Civil Registration System [16]. The registries are described in detail in
Appendix S1. Definitions of drugs, diseases, operations, procedures
and risk scores used in this study are detailed in Appendix S2.
Virtually, all medical care in Denmark is furnished by the national
health authorities, allowing true population-based studies covering all
inhabitants of Denmark. Data were linked using the personal identifi-
cation number (‘CPR number’), a unique identifier assigned to all
Danish citizens at birth or upon immigration [16].
Study drugs. We included the three NOACs with market
authorization in Denmark during the study period: dabigatran etexilate
(Pradaxa), rivaroxaban (Xarelto) and apixaban (Eliquis).
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Dabigatran was marketed for AF in Denmark on 1 August 2011,
rivaroxaban on 1 February 2012 and apixaban on 1 December 2012.
‘Low-dose’ treatment was defined as doses ≤110 mg twice daily for
dabigatran, ≤15 mg once daily for rivaroxaban and ≤2.5 mg twice
daily for apixaban. VKA consisted of warfarin and phenprocoumon,
which are the only VKAs marketed in Denmark. During the study
period, warfarin constituted 97% of the total sale of VKAs [17].
Study population. We identified all Danish individuals filling a
prescription for a NOAC from August 2011 through February 2016.
The index date was defined as the date of the first filling of a NOAC
for a given patient. As we focused on NOAC use in AF patients, we
required that patients were registered with a diagnosis of AF in the
Patient Registry prior to or up to 60 days after the first NOAC
prescription. The 60-day period was chosen to ensure inclusion of
patients diagnosed with AF in primary care, as they will often initiate
anticoagulant therapy before being registered with an AF diagnosis at
the hospital [2]. The diagnosis of AF in the Patient Registry is highly
valid with a positive predictive value of 98% [18,19]. We further
excluded individuals potentially using NOAC for other indications
registered in the Patient Registry, that is individuals with any history
of venous thromboembolic disease at any time prior to the date of
NOAC initiation, as well as individuals with hip or knee replacement
procedures within two weeks before and five weeks after the first
dispensing of a NOAC. Lastly, each patient had to have been a
resident in Denmark for a minimum of 5 years and had to be
≥18 years old at the time of filling the first NOAC prescription.
Analyses. We divided the analyses into three subheadings collectively
describing and exploring treatment changes during NOAC treatment in
AF patients. All analyses were specified by previous use of VKA and
by type of NOAC. Previous use of VKA was defined as having filled
at least one VKA prescription within 2 years prior to the index date.
All calculations were performed using STATA Release 14.0
(StataCorp, College Station, TX, USA).
Baseline characteristics of NOAC initiators. We assessed baseline
characteristics of all AF patients initiating a NOAC during the study
period. The following characteristics were included: (a) age at index
date and sex; (b) chronic diseases associated with an increased risk of
bleeding and/or thromboembolism (including registration of the
following diagnoses within 5 years prior to index date: alcohol abuse,
cancer, chronic renal failure, diabetes, ischaemic heart disease, liver
failure, peripheral arterial disease, any previous bleeding and
ischaemic stroke/transient ischaemic attack); (c) prescriptions for
platelet inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs) or
selective serotonin reuptake inhibitors (SSRIs) filled within 180 days
before index date; (d) type of NOAC and start dose; (e) CHAD2DS2-
VASc score [20] (Appendix S3); and finally (f) HAS-BLED score [21]
(Appendix S3).
To assess medication changes in relation to initiation of NOAC
treatment, we further assessed the use of platelet inhibitors, NSAIDs
and SSRIs within 180 days after index date.
Treatment changes during NOAC therapy. We considered a patient as
treated with a given NOAC from the day of filling a prescription and
for the subsequent number of days corresponding to the number of
tablets in a package for rivaroxaban (used once daily) or half the
number of tablets in a package for dabigatran and apixaban (used
twice daily). Finally, a 30-day grace period was added to account for
minor non-compliance and irregular prescription refills.
Following patients from their index date, we determined the propor-
tion of patients who had (i) switched to another NOAC, defined as
filling a prescription for a NOAC different from the one first filled;
(ii) switched to VKA, defined as filling a prescription for VKA; or
(iii) discontinued anticoagulant treatment, defined as the first period
without a prescription for the same or another oral anticoagulant last-
ing >60 days beyond the end of supply of the latest prescription (in-
cluding the grace period). Follow-up was terminated upon switches to
VKA and discontinuations but was continued when switching to
another NOAC. Furthermore, study individuals were censored upon
death, migration and end of the study period.
Distribution and prediction of treatment changes by baseline
characteristics. For each subgroup, we determined the proportion of
patients with a switch from NOAC to VKA and the proportion of
patients with discontinuation within 1 year after filling the first NOAC
prescription. To contribute to this analysis, a minimum follow-up of
1 year after the index date was thus required. Further, we entered all
baseline characteristics into a multivariate logistic regression model, to
assess whether any characteristics were associated with these specific
treatment changes.
Ethics. The study was approved by the Danish Health Data
Authority. According to Danish law, approval from an Ethics
Committee is not required for purely register-based studies [22].
Results
We identified 94,023 individuals initiating a NOAC within
the study period. After exclusions (Figure S1), 50,632 eligible
patients were included. The number of new NOAC users
increased every year in the study period. Overall, dabigatran
was the most commonly used NOAC (49.9%, n = 25,243)
(table 1), whereas rivaroxaban and apixaban were initiated by
24.9% (n = 12,627) and 25.2% (n = 12,753) of the patients,
respectively. In 2015, initiation of apixaban was more com-
mon (49.0%) than initiation of rivaroxaban (35.7%) and dabi-
gatran (15.4%).
Baseline characteristics of NOAC initiators.
The median age of NOAC initiators was 74 years (interquar-
tile range 67–82), and the vast majority (86.5%) had a
CHA2DS2-VASc score ≥2. Overall, 30.1% (n = 15,256) had
been treated with a VKA prior to NOAC initiation, that is
switched from VKA to NOAC. Among individuals initiating a
NOAC in the period of 2011–2012, 42.5% were previous
VKA users, while this was the case for 29.0% in 2013–2015.
Compared to VKA-na€ıve NOAC initiators, previous users of
VKA were older and generally had more comorbid conditions
(table 1). Accordingly, they had a higher median CHA2DS2-
VASc score (4 versus 3), were more often started on low-dose
NOAC (46.4% versus 36.9%) and more frequently had a his-
tory of bleeding (19.3% versus 9.3%). Patients initiating apix-
aban had the highest proportion of prior stroke (18.9%),
bleeding (14.0%) and chronic renal failure (4.8%), whereas
dabigatran initiators were younger and had less comorbid con-
ditions compared to other NOACs (table 1).
VKA-na€ıve NOAC initiators had higher baseline use of pla-
telet inhibitors (46.9%) compared to previous VKA users
(28.7%) (table 1). In both groups, the use of platelet inhibitors
was reduced after NOAC initiation, and a similar proportion
of the two groups were classified as concomitant users of
© 2016 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT
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NOAC and platelet inhibitors 180 days after NOAC initiation
(16.8% and 16.0%).
Switching from NOAC to VKA.
A total of 10.1% of NOAC initiators had switched to VKA
within 1 year of follow-up. After 2 and 3 years, this propor-
tion was 13.6% and 16.5%, respectively (fig. 1). When strati-
fying by history of VKA use, 13.7% of those with previous
use of VKA switched back to VKA within the first year of
NOAC treatment (Figure S2a), while the corresponding num-
ber was 8.5% for VKA-na€ıve NOAC initiators (Figure S2b).
When stratifying by individual NOACs, we found that 11.8%,
8.5% and 5.7% had switched to VKA within 1 year for users
of dabigatran, rivaroxaban and apixaban, respectively
(Figure S2c–e).
Predictors of switching to VKA within the first year of
treatment included young age (<55 years), very low
CHA2DS2-VASc score (=0), dabigatran use, previous VKA
use, chronic renal failure and ischaemic heart disease (table 2).
This was similar for individuals with and without prior VKA
use (Table S1) as well as for users of the individual NOACs
(Table S2).
Switching from NOAC to NOAC.
Within the first year of treatment, 4.8% (n = 1,668) had
switched to another NOAC. This proportion increased slightly
(6.0%) after 2 years of follow-up (3). Switching to another
NOAC within 1 year was more common among VKA-na€ıve
NOAC initiators (5.4%) than among VKA-experienced (3.5%)
(Figure S2a–b). For initiators of dabigatran, rivaroxaban and
Table 1.














Female sex 22,822 (45.1%) 6983 (45.8%) 15,839 (44.8%) 10,864 (43.0%) 5894 (46.7%) 6064 (47.5%)
Age (years)
Median (IQR) 74 (67–82) 76 (68–83) 73 (66–81) 72 (65–80) 75 (68–83) 76 (68–84)
<55 2433 (4.8%) 498 (3.3%) 1935 (5.5%) 1455 (5.8%) 491 (3.9%) 487 (3.8%)
55–64 6859 (13.5%) 1707 (11.2%) 5152 (14.6%) 4031 (16.0%) 1494 (11.8%) 1334 (10.5%)
65–74 16,855 (33.3%) 4732 (31.0%) 12,123 (34.3%) 8907 (35.3%) 4099 (32.5%) 3849 (30.2%)
≥75 24,476 (48.3%) 8319 (54.5%) 16,157 (45.7%) 10,850 (43.0%) 6543 (51.8%) 7083 (55.5%)
CHA2DS2-VASc score
Median (IQR) 3 (2–4) 4 (3–5) 3 (2–4) 3 (2–4) 3 (2–5) 4 (2–5)
0 2387 (4.7%) 375 (2.5%) 2012 (5.7%) 1494 (5.9%) 448 (3.5%) 445 (3.5%)
1 4470 (8.8%) 911 (6.0%) 3559 (10.1%) 2477 (9.8%) 1086 (8.6%) 907 (7.1%)
≥2 43,766 (86.5%) 13,970 (91.6%) 29,796 (84.2%) 21,272 (84.3%) 11,093 (87.9%) 11,401 (89.4%)
HAS-BLED score
Median (IQR) 2 (2–3) 2 (2–3) 2 (2–3) 2 (2–3) 2 (2–3) 3 (2–3)
0–2 26,356 (52.1%) 8022 (52.6%) 18,334 (51.8%) 13,652 (54.1%) 6536 (51.8%) 6168 (48.4%)
≥3 24,267 (47.9%) 7234 (47.4%) 17,033 (48.2%) 11,591 (45.9%) 6091 (48.2%) 6585 (51.6%)
Previous VKA use
Yes 15,256 (30.1%) 15,256 (100%) – 8210 (32.5%) 3589 (36.6%) 3013 (23.6%)
No 35,367 (69.9%) – 35,367 (100%) 17,033 (67.5%) 6222 (63.4%) 9740 (76.4%)
Start dose1
High 30,506 (60.3%) 8176 (53.6%) 22,330 (63.1%) 14,247 (56.4%) 8475 (67.1%) 7784 (61.0%)
Low 20,117 (39.7%) 7080 (46.4%) 13,037 (36.9%) 10,996 (43.6%) 4152 (32.9%) 4969 (39.0%)
Comorbidity
Alcohol abuse 1871 (3.7%) 640 (4.2%) 1231 (3.5%) 928 (3.7%) 488 (3.9%) 455 (3.6%)
Cancer 4687 (9.3%) 1655 (10.8%) 3032 (8.6%) 2216 (8.8%) 1223 (9.7%) 1248 (9.8%)
Chronic renal failure 1590 (3.1%) 760 (5.0%) 830 (2.3%) 493 (2.0%) 481 (3.8%) 616 (4.8%)
Diabetes 8498 (16.8%) 3135 (20.5%) 5363 (15.2%) 3982 (15.8%) 2196 (17.4%) 2320 (18.2%)
Hypertension 37,281 (73.6%) 12,273 (80.4%) 25,008 (70.7%) 18,370 (72.8%) 9419 (74.6%) 9492 (74.4%)
Ischaemic heart disease 10,450 (20.6%) 4100 (26.9%) 6350 (18.0%) 5136 (20.3%) 2586 (20.5%) 2728 (21.4%)
Liver failure 180 (0.4%) 67 (0.4%) 113 (0.3%) 86 (0.3%) 43 (0.3%) 51 (0.4%)
Peripheral arterial disease 1573 (3.1%) 679 (4.5%) 894 (2.5%) 696 (2.8%) 431 (3.4%) 446 (3.5%)
Previous bleeding, any 6241 (12.3%) 2939 (19.3%) 3302 (9.3%) 2862 (11.3%) 1589 (12.6%) 1790 (14.0%)
Ischaemic stroke/TIA 7878 (15.6%) 2552 (16.7%) 5326 (15.1%) 3538 (14.0%) 1935 (15.3%) 2405 (18.9%)
Baseline medication use
Platelet inhibitor2 20,986 (41.5%) 4382 (28.7%) 16,604 (46.9%) 10,484 (41.5%) 5101 (40.4%) 5401 (42.4%)
NSAID 6717 (13.3%) 1547 (10.1%) 5170 (14.6%) 3423 (13.6%) 1661 (13.2%) 1633 (12.8%)
SSRI 4656 (9.2%) 1808 (11.9%) 2848 (8.1%) 2216 (8.8%) 1198 (9.5%) 1242 (9.7%)
1Low dose: ≤110 mg twice daily for dabigatran, ≤15 mg once daily for rivaroxaban, ≤2.5 mg twice daily for apixaban.
2Low-dose aspirin, clopidogrel, ticagrelor, prasugrel.
VKA, Vitamin K antagonist; NOAC, non-vitamin K oral anticoagulant; TIA, transient ischaemic attack; NSAID, non-steroidal anti-inflammatory
drug; IQR, interquartile range; SSRI, selective serotonin reuptake inhibitor.
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apixaban, the frequency of switching to another NOAC within
1 year was 5.2%, 5.8% and 2.1% (Figure S2c–e).
Discontinuation of anticoagulant treatment.
After 1 year, 14.4% had discontinued NOAC treatment with-
out switching to another anticoagulant agent. The correspond-
ing proportion was 21.3% after 2 years of follow-up and
25.7% after 3 years (fig. 1). Among VKA-na€ıve NOAC initia-
tors, 15.8% had discontinued treatment within 1 year, whereas
this was the case for 11.4% of individuals with prior VKA
experience (Figure S2a–b). A total of 15.5% and 13.7% of ini-
tiators of dabigatran and rivaroxaban, respectively, had discon-
tinued treatment within 1 year, while this proportion was
lower for apixaban (11.4%) (Figure S2c–e).
Predictors of treatment discontinuation within 1 year were
overall the same as those for switching, apart from previous
VKA use (table 2). Additionally, use of rivaroxaban and
NSAIDs increased the risk of discontinuation. Young age
(<55 years) and a very low CHA2DS2-VASc (=0) score were
the strongest predictors for discontinuation of NOAC treat-
ment (table 2). Patients with a high CHA2DS2-VASc score
(≥2), prior ischaemic stroke/TIA and apixaban use were least
likely to discontinue treatment. Neither stratification by prior
VKA use (Table S1) nor type of NOAC (Table S3) changed
the observed associations.
Discussion
In this large nationwide study on AF patients treated with
NOACs, we found treatment changes to be common: 1 of 3
patients starting a NOAC had switched from VKA, and a sim-
ilar proportion experienced a treatment change during the first
year; half of these patients switched to another anticoagulant
agent and the other half discontinued anticoagulant treatment.
After 3 years, half of all patients were no longer users of the
same NOAC, and 1 of 4 patients had discontinued
anticoagulant treatment. The strongest predictor for treatment
changes was a low risk of stroke. However, most changes
were observed in patients at increased risk of ischaemic stroke
based on their CHA2DS2-VASc score.
Switching from NOAC to VKA was less common in our
study (10.1% within 1 year) than in a previous Danish study
[4], where half of NOAC initiators had switched to VKA
within six months. These results were based on a small sample
(n = 1,639) of early NOAC users in only one of five Danish
regions, which may explain the divergent results. In a more
recent and nationwide Danish study [5], 9.4% of VKA-na€ıve
dabigatran initiators switched to warfarin within 1 year, that is
a result nearly identical to ours. In the Dresden NOAC reg-
istry, only 5% of NOAC initiators (with and without previous
VKA use) had switched to VKA within 18 months [9]. This
markedly lower switch rate most likely reflects a different atti-
tude towards VKA treatment or motivation for use of NOAC
in AF between European countries. In the most recent Euro-
pean AF guidelines, NOAC is preferred over VKA for stroke
prophylaxis in AF [1]. In contrast, Danish guidelines [23] con-
sider VKA and NOAC as equal treatment alternatives, as long
as ‘high-quality VKA treatment’ (defined as time in the thera-
peutic range of INR ≥ 70%) can be expected or demonstrated.
Consequently, this may result in differences in the manage-
ment of NOAC-treated patients between countries.
While the consequences of discontinuation of anticoagulant
therapy in AF are well established [7,24], knowledge on the
safety implications of switching between anticoagulant agents
is sparse. Beyer-Westendorf et al. found 30-day rates for
bleeding and thromboembolism of 11.6% and 1.1%, respec-
tively, in patients switching from warfarin to NOAC in the
Dresden NOAC Registry [6]. However, the corresponding
rates for patients continuing warfarin therapy were not pre-
sented, thus precluding estimation of relative risks. In a large
cohort of Danish AF patients, Larsen et al. found similar
bleeding rates in warfarin-treated patients switched to dabiga-
tran and in patients persisting to warfarin [25]. Switching from
warfarin to dabigatran was, however, associated with a twice
as high risk of stroke/TIA in the subgroup of patients with a
history of these specific conditions [26]. To the best of our
knowledge, the safety of switching from NOAC to VKA has
only been assessed in post hoc analyses of randomized clinical
trials, in which it was associated with a 3 times increased 30-
day risk of both bleeding and thromboembolism [7,8].
Current knowledge on the reasons leading to anticoagulant
switching primarily pertains to the switch from VKA to
NOAC, which also was the most frequent type of switch in
the present study. In the study mentioned above, Beyer-Wes-
tendorf et al. [6] found ‘unstable INR’ as the most common
reason (58%) for switching from VKA to NOAC among 568
AF patients, and ‘bleeding complications’ were the second
most common reason (18% of patients) [6]. Other studies [27–
29] support that unstable INR levels is a major reason for
switching from VKA to NOAC. Of note, unstable INR can
have several causes including low adherence [30], and it is
currently unknown which AF patients with unstable INR val-
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Fig. 1. Treatment changes among all NOAC initiators with atrial fib-
rillation. Cumulative proportion of NOAC initiators with atrial fibrilla-
tion discontinuing treatment, switching to VKA, switching to another
NOAC and continuing treatment. Denmark, August 2011–February
2016.
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present study, information concerning the quality of INR con-
trol among patients switched from VKA to NOAC was not
available.
Discontinuation of anticoagulant therapy is a well-known
consequence of both major and minor bleeding events
[9,32,33], although recent studies [34,35] have questioned the
appropriateness of this. In our study, a high HAS-BLED score
(≥3) at baseline was not a predictor of discontinuation, which
may reflect use of the low NOAC doses in these patients [26].
Presumed lack of indication of anticoagulant therapy may also
be an important determinant of discontinuation, indicated by
the finding of stable sinus rhythm (41%) as the most common
cause of discontinuation among 32 dabigatran users in the
Dresden NOAC Registry [36] and by the high prevalence of
discontinuation among patients with CHA2DS2-VASc score=0
in the present study.
Table 2.
Predictors of early treatment changes. Switching to VKA and discontinuation within 1 year of initiation among NOAC users with atrial fibrillation
according to baseline characteristics and adjusted odds ratios1 for associations between baseline characteristics and treatment changes. Odds ratios




Switch from NOAC to VKA (n = 3,828) Discontinuations (n = 7908)
Switch frequency Odds ratio (95% CI)
Discontinuation
frequency Odds ratio (95% CI)
Sex
Female 15,394 10.3% 1.00 (ref.) 19.9% 1.00 (ref.)
Male 19,233 11.7% 0.97 (0.90–1.04) 25.2% 1.11 (1.05–1.18)
Age (years)
<55 1807 20.1% 1.56 (1.33–1.82) 51.3% 2.45 (2.16–2.77)
55–64 5195 13.6% 1.03 (0.92–1.16) 29.1% 1.09 (1.00–1.20)
65–74 12,402 11.4% 1.00 (ref.) 20.2% 1.00 (ref.)
≥75 15,223 8.8% 0.85 (0.78–0.94) 19.4% 1.00 (0.93–1.08)
CHA2DS2-VASc score
0 1776 19.8% 1.70 (1.41–2.06) 59.8% 3.98 (3.44–4.61)
1 3360 13.5% 1.18 (1.03–1.35) 28.2% 1.32 (1.19–1.46)
≥2 29,491 10.2% 1.00 (ref.) 20.0% 1.00 (ref.)
HAS-BLED score
0–2 18,294 12.3% 1.06 (0.94–1.19) 25.8% 0.95 (0.87–1.04)
≥3 16,333 9.6% 1.00 (ref.) 19.5% 1.00 (ref.)
Type of NOAC
Dabigatran 21,852 13.0% 1.00 (ref.) 25.5% 1.00 (ref.)
Rivaroxaban 6859 9.2% 0.72 (0.65–0.79) 20.4% 0.88 (0.82–0.95)
Apixaban 5916 6.2% 0.50 (0.44–0.56) 15.8% 0.64 (0.58–0.69)
Previous VKA use
No 23,681 9.2% 1.00 (ref.) 22.9% 1.00 (ref.)
Yes 10,946 15.1% 1.77 (1.64–1.91) 22.7% 0.96 (0.91–1.02)
Start dose2
High 21,415 12.2% 1.00 (ref.) 23.8% 1.00 (ref.)
Low 13,212 9.2% 0.81 (0.74–0.89) 21.3% 1.11 (1.03–1.18)
Comorbidities3
Alcohol abuse 1280 8.9% 0.73 (0.60–0.90) 26.1% 1.08 (0.94–1.24)
Cancer 2774 9.5% 0.90 (0.79–1.03) 22.5% 1.10 (1.00–1.21)
Chronic renal failure 870 13.1% 1.58 (1.28–1.96) 25.1% 1.36 (1.16–1.61)
Diabetes 5606 10.0% 0.88 (0.80–0.97) 20.0% 0.94 (0.87–1.01)
Hypertension 25,371 10.8% 1.12 (1.00–1.24) 20.7% 0.96 (0.89–1.04)
Ischaemic heart disease 7094 12.1% 1.25 (1.14–1.37) 23.7% 1.34 (1.26–1.44)
Liver failure 102 11.8% 1.23 (0.66–2.29) 39.2% 2.01 (1.32–3.07)
Peripheral arterial disease 916 8.2% 0.76 (0.60–0.97) 21.4% 1.08 (0.92–1.27)
Previous bleeding, any 4065 10.8% 1.03 (0.91–1.15) 23.2% 1.12 (1.02–1.22)
Ischaemic stroke/TIA 5288 7.9% 0.78 (0.69–0.87) 15.3% 0.68 (0.62–0.74)
Baseline medication use3
Platelet inhibitor4 14,551 9.6% 0.94 (0.86–1.04) 19.8% 0.81 (0.75–0.87)
NSAID 4627 11.3% 1.08 (0.97–1.20) 24.2% 1.06 (0.98–1.14)
SSRI 2965 8.4% 0.77 (0.67–0.89) 19.1% 0.89 (0.80–0.98)
1Adjusted for age, sex and baseline characteristics.
2Low dose: ≤110 mg twice daily for dabigatran, ≤15 mg once daily for rivaroxaban, ≤2,5 mg twice daily for apixaban.
3These are variables with binary responses (yes/no), but only the ‘yes’ is presented here. ‘No’ serves as reference.
4Low-dose aspirin, clopidogrel, ticagrelor, prasugrel.
VKA, Vitamin K antagonist; NOAC, non-vitamin K oral anticoagulant; TIA, transient ischaemic attack; NSAID, non-steroidal anti-inflammatory
drug; SSRI, selective serotonin reuptake inhibitor.
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Users of apixaban showed better persistence than users of dabi-
gatran and rivaroxaban. This is in accordance with other observa-
tional studies based on ‘real-life’ patients [10], but contrasts with
phase III trials, where users of the three NOACs showed similar
persistence [37–39]. Although apixaban may be better tolerated
than other NOACs, the finding may reflect selection bias. As
shown in the present and other studies [2,10], apixaban is pre-
ferred in AF patients with a high thromboembolic risk, that is the
patients most likely to persist to treatment [5]. Moreover, physi-
cians were already experienced with the selection and manage-
ment of NOAC treated patients when apixaban entered the
marked in late 2012. However, as users of apixaban also had bet-
ter persistence in the analysis adjusting for these factors, this dif-
ference in persistence should be further explored.
The principal strength of the present study is the nationwide
analyses, including all Danes registered with AF and initiating
a NOAC since the date of marketing of the first NOAC in
Denmark to the beginning of 2016. Other strengths include
the completeness of the registries employed [14,16] as well as
the high validity of the AF diagnosis [18,19]. There are limita-
tions as well. In the restriction to patients with a known AF
diagnosis, an approach commonly used in studies on NOAC
use in AF patients [2,5,25], we excluded 22.9% of all NOAC
initiators as they did not have a hospital diagnosis compatible
with any approved indication of NOAC use. A substantial but
unknown proportion of these patients are likely to receive
NOAC treatment because of unregistered AF (e.g. cases of AF
handled in primary care alone). This may be a source of selec-
tion bias, if treatment patterns among these patients are differ-
ent from the study population. Further, although pharmacy
dispensing information is generally considered a valid measure
of drug exposure [40], misclassification remains possible [41].
Finally, although the majority of diagnoses used to identify
comorbidity and clinical events in the study have been vali-
dated with acceptable results [15], the validity of some of the
used diagnoses remains unknown.
In conclusion, we found switching from VKA to NOAC,
and to a lesser extent from NOAC to VKA, to be common, as
were treatment discontinuation. Young age and low
CHA2DS2-VASc score were the strongest predictors of switch-
ing from NOAC to VKA and discontinuation. However, based
on their CHA2DS2-VASc score, the majority of patients expe-
riencing a treatment change had an increased risk of ischaemic
stroke. The extent and patterns of treatment changes found in
this study call for further exploration of the risks and benefits
associated with changes in oral anticoagulant therapy.
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